IRadimed Raised FY24 Adj EPS To $1.64 -$1.67 From $1.52 -$1.62 (Vs $1.56 Est.); Revenue To $72.7M-$73.1M From $$72M-$74M Vs $72.62M Est.
Portfolio Pulse from Lekha Gupta
IRadimed has raised its FY24 adjusted EPS guidance to $1.64-$1.67 from $1.52-$1.62, surpassing the $1.56 estimate. Revenue guidance is set at $72.7M-$73.1M, slightly above the $72.62M estimate.
October 31, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IRadimed has increased its FY24 adjusted EPS guidance to $1.64-$1.67, exceeding the previous range and analyst estimates. Revenue guidance is also slightly above expectations.
The upward revision in EPS guidance indicates improved profitability expectations, which is a positive signal for investors. The revenue guidance, while slightly above estimates, supports the positive outlook. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100